This clinical study is testing a new drug called ivonescimab for people with a type of lung cancer called metastatic NSCLC (non-small cell lung cancer). Metastatic means the cancer has spread to other parts of the body. The study focuses on patients with high levels of a protein called PD-L1 in their tumors. The study aims to see how long patients live and how long they go without the cancer getting worse.

To join, you must be 18 or older, have a good physical condition (ECOG score 0-1), and have a life expectancy of at least 3 months. You should not have had any previous treatments for metastatic NSCLC.

• The study requires patients to have regular check-ups and might involve some travel.
• There might be risks, but it could lead to better care for future patients.
• Participants might receive compensation for their time and travel.